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A channelopathy mutation in 
the voltage-sensor discloses 
contributions of a conserved 
phenylalanine to gating properties 
of Kv1.1 channels and ataxia
Sonia Hasan1, Cecilia Bove  2, Gabriella Silvestri3, Elide Mantuano4, Anna Modoni3, Liana 
Veneziano4, Lara Macchioni2, Therese Hunter5, Gary Hunter5, Mauro Pessia2,5 & Maria Cristina 
D’Adamo5
Channelopathy mutations prove informative on disease causing mechanisms and channel gating 
dynamics. We have identified a novel heterozygous mutation in the KCNA1 gene of a young proband 
displaying typical signs and symptoms of Episodic Ataxia type 1 (EA1). This mutation is in the S4 helix 
of the voltage-sensing domain and results in the substitution of the highly conserved phenylalanine 303 
by valine (p.F303V). The contributions of F303 towards K+ channel voltage gating are unclear and here 
have been assessed biophysically and by performing structural analysis using rat Kv1.2 coordinates. 
We observed significant positive shifts of voltage-dependence, changes in the activation, deactivation 
and slow inactivation kinetics, reduced window currents, and decreased current amplitudes of both 
Kv1.1 and Kv1.1/1.2 channels. Structural analysis revealed altered interactions between F303V and 
L339 and I335 of the S5 helix of a neighboring subunit. The substitution of an aromatic phenylalanine 
with an aliphatic valine within the voltage-sensor destabilizes the open state of the channel. Thus, F303 
fine-tunes the Kv1.1 gating properties and contributes to the interactions between the S4 segment and 
neighboring alpha helices. The resulting channel’s loss of function validates the clinical relevance of the 
mutation for EA1 pathogenesis.
Voltage-gated potassium channels (Kv) play key roles in neurotransmission and nerve cell physiology1 and are 
of high therapeutic relevance2. Strategically clustered at critical subdomains such as the axon initial segment3, 
juxtaparanodal regions of the Ranvier’s node4, as well as in synaptic nerve terminals5, Kv1 channels are known 
key regulators of excitability. They open at voltages close to action potential (AP) threshold to reduce excitability 
by limiting nodal re-excitation6, shaping the presynaptic AP waveform and controlling transmitter release at 
synaptic terminals7. Accordingly, mutations that result in dysfunctional Kv1.1 channels are likely to result in 
impairments in neuronal excitability and neurotransmission. Of particular clinical importance is the Kv1.1 chan-
nelopathy that is predominantly linked to Episodic Ataxia type 1 (EA1). EA1 is an autosomal dominant disorder 
characterized by frequent, albeit brief, attacks of uncoordinated movements (ataxia) and involuntary repetitive 
muscular contractions (myokymia). The disorder presents primarily by means of heterozygous point mutations in 
the KCNA1 (Kv1.1) gene, located on chromosome 12p138–10. Kv1.1 co-assembles with α-subunits of other mem-
bers of the Kv1 family to form heterotetrameric channels with biophysical and pharmacological properties that 
are distinct from homotetramers made up of their contributing subunits11–16. Both in the periphery17, 18 and in the 
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brain19, 20 Kv1.1 is mostly found co-assembled with Kv1.2 subunits. A mutation in Kv1.1 affects the function of the 
Kv1.1/1.2 heteromeric channel to which they contribute21. A number of functional studies on Kv1.1 mutations all 
report loss of function of the channel1, 8, 21–29. Yet, despite this consensus, phenotypic heterogeneity such as severity 
of ataxia and presence of additional features such as epilepsy and hyperthermia exist24, 30, 31 and may be connected 
to differences in mechanisms of dysfunction, altered specific channel parameters or epigenetics30, 32–34.
Structurally, Kv channels are composed of four subunits each of which contains six transmembrane-spanning 
segments (S1 through S6) with cytoplasmic N- and C-terminal domains (Fig. 1c). The S1–S4 segments comprise 
the voltage-sensing domain, which senses the membrane potential and controls the gating of the pore domain 
(S5–S6). Kv1.1 α-subunits make up channels that mediate the non-inactivating outward delayed-rectifier potas-
sium current14. The positively charged amino acids in the S4 segment play a central role in the voltage-dependence 
of Kv1.1 channels. In particular, the characteristic low activation threshold and distinct activation-deactivation 
kinetics features12, 14 of the channel are crucial for an immediate outward current response to fast depolarizing 
stimuli, allowing for an effective prevention of excessive neuronal excitation16. It has been proposed that the 
activated state (i.e., the upstage) of the voltage-sensors is stabilized by interactions between a highly conserved 
phenylalanine residue located in segment S2 (F233) and its hydrophobic neighbors, and that mutations of these 
hydrophobic residues specifically destabilize the open-state and cause a dramatic acceleration in deactivation 
gating kinetics35. Although several studies have focused on the role of F233 to Shaker-like channel gating36–39, the 
contribution of the highly conserved phenylalanine residues located within segment S4 is not fully understood. 
Here, we identified a new mutation in the Kv1.1 channel of family members displaying typical symptoms of 
EA1 that changes the highly conserved F303, located adjacent to the positively charged residue (K304) in the S4 
segment, into a valine (Fig. 1b-d). What functional role does this F303 residue play? The assessments of the bio-
physical properties of the channel in which F303 was replaced by a valine indicated that the voltage-dependence 
and gating kinetics of both homomeric and heteromeric Kv1.1 and Kv1.1/1.2 channels are remarkably affected, 
providing novel insights into both the role of F303 in channel gating and the mechanisms accounting for the 
neuronal hyperexcitability phenotype displayed by the patient.
Methods
Clinical and neurophysiologic examination. Studies involving the proband and his family complied 
with the Helsinki Declaration and was approved by the Ethical Committee of Catholic University of Sacred Heart, 
Fondazione Gemelli, Rome, Italy. Written informed consent for participation and publishing were obtained from 
all subjects (and both parents on behalf of the proband aged <18 years) included in the study.
The neurophysiologic evaluation included sensory and motor nerve conduction studies combined with the 
measurement of F-wave latencies. Patients were examined in a warm comfortable room; the skin temperature 
was maintained above 32 °C. Motor nerve conduction studies were carried out on ulnar and tibial nerves. The 
stimulus was an electrical square pulse of 0.2 ms; current intensity was 150% of that needed to obtain maximal 
Figure 1. Detecting and analyzing the mutation. (a) Pedigree of patient’s family. The arrow indicates the 
proband, black symbols indicate affected subjects. (b) DNA sequencing chromatogram of a section of KCNA1 
(Kv1.1) exon 2 showing the heterozygous mutation segregating in the family. The arrow indicates the c907 T > G 
nucleotide substitution. (c) Schematic topology model of the human Kv1.1 subunit showing approximate site for 
the F303V mutation in the S4 segment. (d) Alignment of the region of interest for Kv1.1 channels from various 
species using MUSCLE 3.6. The arrow indicates the affected phenylalanine.
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Compound Muscle Action Potential (CMAP) amplitude. The position of the recording electrodes was considered 
optimal when the CMAP showed maximal amplitude and negative onset. As for ulnar nerves, the recording 
monopolar surface electrode was placed on abductor digiti quinti and referred to the first phalanx of the fifth fin-
ger. The CMAP of the tibial nerves was recorded from abductor hallucis and referred to the metatarsal-phalangeal 
joint of the big toe. Sensory nerve conduction studies were carried out on the sural nerve. It was stimulated 
antidromically: the recording surface electrode was placed under the lateral malleolus bone and the stimulating 
electrode was kept at a distance of 12 cm from the active recording electrode.
Genetic analysis. DNA was isolated from peripheral blood using standard methods. KCNA1 coding regions 
and exon-intron boundaries were amplified by polymerase chain reaction (PCR) using the following primer pairs:
EA1-F21: AGAAGCAGAGAGGGTGGCAG
EA1-REV2: AAGAAGTCCGTCTTGCTGGG
and
EA1-F1/7B: CCACGGTCATCTACAATTCCAA
EA1-REV: CTTGAAAGCTTCTGGTTCACCACC
To detect the genetic defect underlying the pathology, the PCR products were sequenced using an automated 
Sanger dideoxy method. The obtained DNA fragments were sequenced by Eurofins MWG Operon Sequencing 
Service (http://www.mwg-biotech.com/). In silico prediction tools PolyPhen (http://genetics.bwh.harvard.edu/
pph/) and SIFT (http://sift.jcvi.org/) were used to predict the pathogenicity of the variants found.
Production of KCNA1 constructs. Human Kv1.1 cDNA was subcloned into a pBF oocyte expression vec-
tor. The mutation p.F303V was introduced by site-directed mutagenesis performed according to the QuikChange 
protocol (Stratagene, La Jolla, CA) and was verified by automated sequencing. The concentration of the in vitro 
transcribed cRNA was quantified by electrophoresis with ethidium bromide staining and spectrophotometric 
analysis.
Heterologous expression of KCNA1. Wild-type and mutant channels were expressed in Xenopus laevis 
oocytes as described in D’Adamo et al., 199823. All animal handling was in accordance with international stand-
ards of animal care, the Italian Animal Welfare Act, approved by the local Veterinary Service Authority, and the 
NIH Guide for the Care and Use of Laboratory Animals. Xenopus laevis were deeply anesthetized with an aer-
ated solution containing 3-aminobenzoic acid ethyl ester methanesulfonate salt (5 mM) and sodium bicarbonate 
(60 mM), pH 7.3. Stage V–VI Xenopus Laevis oocytes were isolated, digested with collagenase, each injected 
with 50 nl cRNA and incubated at 16 °C in ND96 solution containing (mM): NaCl 96, KCl 2, MgCl2 1, CaCl2 1.8, 
HEPES 5, gentamicin 50 μg/ml. Xenopus laevis underwent no more than two surgeries, separated by at least 3 
weeks.
Electrophysiology. Two-electrode voltage-clamp recordings (TEVC) were performed as previously 
described23. Briefly, whole-cell currents were recorded using TEVC on oocytes at ~22 °C. Recordings were made 
on days 1 to 7 after cRNA injection, and using a GeneClamp 500 amplifier (Axon Instruments, Foster City, CA) 
interfaced to a PC computer with an ITC-16 interface (InstruTech, Port Washington, NY). Microelectrodes were 
pulled to a tip resistance of <1 MΩ and backfilled with 3 M KCl. The extracellular solution contained (mM): NaCl 
96, KCl 2, MgCl2 1, CaCl2 1.8, HEPES 5, pH 7.4. Recordings were filtered at 2 kHz and acquired at 5 kHz with 
Pulse software and analyzed with either PulseFit (HEKA, Germany) or Origin 8 (OriginLab, Northampton, MA). 
Leak and capacitative currents were subtracted using a P/4 protocol.
Structural analysis. The coordinates for rat Kv1.2 channel were taken from PDB entry 3LUT40. To locate 
the position of the mutated residue in the rat Kv1.2 channel structure, sequence alignments were performed with 
ClustalW using the following channel homologs: human Kv1.1 (3736), Shaker (P08510), and Kv1.2/2.1 Chimera 
(P62483). The final sequence alignment was further refined using Muscle 2.640. EA1 mutations were performed 
in silico by substituting the wild type residue with the desired mutation. The human Kv1.1 structural homology 
model was constructed utilizing the Swiss-Model server41–43 and amino acid sequence NP_000208 with the Kv1.2 
structure, 3LUT, serving as template (above 84% sequence homology). Amino acid interaction distances were 
measured using PyMOL44.
Statistical Analysis. Statistical analysis was performed using the software programs Prism 6 (GraphPad 
Software, San Diego, CA) and Origin 8 (OriginLab, Northampton, MA). All data are shown as mean ± standard 
error (SE). Observed differences were evaluated by two-tailed unpaired Student’s t-test and were considered sig-
nificant if p < 0.05.
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
Clinical Description. All the symptomatic family members referred since childhood the occurrence of brief 
episodes, lasting a few minutes or even less, characterized by dizziness, gait unsteadiness and speech impairment 
modifications. These episodes, usually triggered by physical exercise or emotional stress, were mild and infre-
quent in the oldest patients (pt I2 and I3 in Fig. 1a), while occurring more frequently in pt II1 and in her 14-year-
old son III1 (Fig. 1a), the family proband, in which both the intensity and the recurrence of ataxic episodes were 
disabling.
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Interictal neurological examination showed a fine postural tremor distally in the upper extremities both in the 
proband and his mother pt II1, showed nystagmus in the extreme lateral gaze and postural tremor in the upper 
limbs. Finally pt I2, his maternal grandmother, who is the oldest affected family member, manifested rare facial 
myokymia, diffuse postural limb tremor and some difficulties in tandem walking. All patients had normal muscle 
tone and trophism, normal reflexes and no sensory deficit. In the proband, we were able to trigger a brief episode 
of gait ataxia and dysarthria, lasting a few seconds that was elicited by physical exercise (short run).
Neurophysiologic studies performed in the proband and in his affected mother showed the presence of repet-
itive components of CMAP in ulnar as well as in tibial nerves. They were evident both on routine motor stud-
ies and on F-wave studies, making F-waves unrecognizable. Sensory conduction studies were unremarkable. In 
order to investigate the neuromuscular transmission (NMT) in these patients, we also performed repetitive nerve 
stimulation tests at 3, 20 and 50 Hz, prolonged for 10 stimuli. Repetitive nerve stimulation tests at 3 Hz did not 
result in any significant variation in CMAP amplitude. Conversely, a train of stimuli at 20 Hz or 50 Hz showed a 
decrement of the amplitude of the first CMAP elicited followed by an increment of the second CMAP amplitude 
elicited (decrement-increment phenomenon), similar to what is usually observed in organophosphate intoxica-
tion (Fig. 2). These findings confirmed the abnormal neuromuscular transmission exhibited in Kv1.1 knock-in 
ataxic mice18 pointing out the role of juxtaparanodal K+ channels in dampening the excitability of motor nerve 
axons during fatigue.
Identifying the Mutation as c. 907 T > G, p. F303V. Genetic analysis (Fig. 1b) showed that the patient 
carries a heterozygous T > G substitution in exon 2 of the KCNA1 gene at nucleotide 907 (NM_000217.2: 
c.907T > G) resulting in a substitution of phenylalanine at codon 303 by a valine (p.F303V). Protein-homology 
analysis identified a highly evolutionary conserved phenylalanine at position 303 (Fig. 1d) located within the S4 
segment of the voltage-sensor portion of the Kv1.1 channel (Fig. 1c). According to PolyPhen-2 tool, the mutation 
was probably damaging with a score 0.999. According to SIFT, the mutation was deleterious with a score 0.001.
F303V reduces whole-cell Kv1.1 current amplitude. For current measurements, oocytes were depolar-
ized from a holding potential of −80 mV to a voltage of +60 mV for 500 ms. Currents and mean values reported 
are from recordings taken 5 days after injection, i.e. during peak mutant expression thereby allowing for a bet-
ter mutant current bioanalysis (see Supplementary section, Figure S1). Cells injected with homomeric Kv1.1WT 
cRNA (50 nl, 5 ng/µl) showed robust potassium delayed-rectifying currents (14 ± 1.6 µA, n = 10) that were sig-
nificantly greater than those recorded from cells expressing the same amount of homomeric Kv1.1F303V channels 
(0.5 ± 0.08 µA, p < 0.0001 n = 10; Fig. 3a and b). In the heterozygous state both normal and mutant alleles may 
be expressed. Co-injecting equal amounts of Kv1.1WT and KvF303V cRNA (2.5 ng/µl each, 50 nl total injected vol-
ume) in oocytes allows for the co-expression of wild-type and mutant subunits thereby possibly mimicking the 
heterozygous state of the patient. The mean current obtained when both subunits were co-expressed in a 1:1 ratio 
was 7.7 ± 1 µA (n = 10), a significantly smaller mean current than that obtained from homomeric WT channels 
(p < 0.005) and larger than that from homomeric mutant channels (p < 0.0001: Fig. 3a and b). On the other 
hand, currents from heteromeric Kv1.1/1.2 channels, co-expressing F303V with Kv1.2 in a 1:1 ratio, resulted in 
a whole-cell current mean (13 ± 1.3 µA, n = 8) at +60 mV that was significantly smaller than that of the control 
Kv1.1WT/1.2 (37 ± 4 μA, n = 8, p < 0.001; Fig. 3c and d).
Effect of F303V on voltage-dependent activation of Kv1.1 channels. To analyze the effect of 
the mutation on the voltage-dependence of Kv1.1 current activation, tail current amplitudes were recorded at 
−50 mV after 200 ms pre-pulse commands from −80 to +80 mV (Fig. 4). The peak amplitudes of the tail currents 
(Fig. 4d and e) were plotted as a function of the pre-pulse potential and the mean values were fitted with the 
Boltzmann function Po(V) = 1/{1 + exp[(V1/2 − V)/k]}, where V1/2 is the half-maximal voltage, and k the slope 
factor. The F303V mutation resulted in a significant change in the open probability (Po–V) curve and hence in 
a 36 mV right shift of the V1/2 value to more positive potentials (Fig. 4c and e). Kv1.1WT/F303V heteromers had a 
Po–V curve intermediate in position between the Kv1.1WT and KvF303V homomer curves, and had a significantly 
different V1/2 compared to the wild type and the homomer (Fig. 4c; Table 1). The slope factor, derived from 
the Boltzmann fit of tail currents, was greater for the KvF303V and Kv1.1WT/F303V curves than that of the Kv1.1WT 
(Table 1). A mutation-induced shift to more positive potentials (16 mV shift) and increases in slope factor were 
also obtained for the Kv1.1WT/Kv1.2 heteromer (Fig. 4f; Table 1).
Figure 2. CMAPs evoked by repetitive nerve stimulation (RNS) of the tibial nerve at a high frequency (50 Hz). 
The decrement-increment phenomenon is indicated by the arrow.
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Effect of F303V on activation and deactivation kinetics. To determine changes in activation and 
deactivation kinetics, activation time constants derived from double exponential fits of the rising phase of 
the test currents and deactivation time constants from single exponential fits of tail currents were plotted as a 
function of membrane potential (Fig. 5c and f). The plotted data points were fitted with the equation τ = τV1/2 
exp{(V-V1/2)/k}, where τV1/2 is the time constant at the V1/2 of the channels and k is the slope factor for the voltage 
dependence of the time constants. Kinetic analysis revealed that, compared to Kv1.1WT currents, a slower activa-
tion yet faster deactivation was observed for Kv1.1F303V and Kv1.1WT/F303V currents (Fig. 5a-c). The same change 
in gating kinetics, albeit smaller, was observed for the F303V mutation in Kv1.1/1.2 heterotetramer (Fig. 5d-f).
Effect of mutation on the voltage-dependence of slow inactivation and window current. As in 
the voltage-dependence of activation, the mutation right shifted the inactivation curves (Fig. 6a and b) towards 
more positive values. The V1/2 of the slow inactivation for Kv1.1F303V was right shifted 20 mV compared to Kv1.1WT 
(Table 1). As for the inactivation of the Kv1.1/1.2 heterotetramers, the V1/2 was 9 mV more positive. On the other 
hand, the slope factor of inactivation curve was statistically different from the wild-type only for the homote-
trameric Kv1.1F303V curve (Table 1).
The window current, a measure of the number of inactivating ion channels that are tonically active, was quan-
tified by using an integration gadget (OriginLab, Northampton, MA) to integrate the overlapping triangular area 
between steady-state activation and inactivation curves (Fig. 6c and d). This overlapping area was smaller in the 
curves derived from oocytes expressing the mutation, both in the Kv1.1F303V homotetrameric (2/5th the area of the 
WT) and Kv1.1WT/F303V heterotetrameric (4/5th that of the WT) channels (Fig. 6c; Table 1). This reduction in area 
was also apparent in curves derived from Kv1.1F303V/Kv1.2 when compared to its WT control counterpart (Fig. 6d; 
Table 1). The voltage point whereby the Kv1.1WT activation and inactivation curves intersect (the peak of the 
triangle) were right shifted by the mutation to more positive potentials. Specifically, there was a 26 mV shift for 
Kv1.1F303V and a 6 mV shift for the co-expressed Kv1.1WT/Kv1.1F303V. As for the Kv1.1F303V/Kv1.2 heterotetramers, 
there was a similar 10 mV positive shift away from its wild-type Kv1.1/Kv1.2 control counterpart.
Effect of mutation on slow inactivation and recovery. To determine the changes in slow inactivation, 
the oocytes were depolarized at +60 mV for 3.5 minutes. The decaying phase of the current was then fitted with 
a double exponential to compute fast and slow kinetics of inactivation. Although there was no apparent change 
in the slow inactivation (Figure S2), the residual current (final current divided by peak current, IFinal/IPeak), for 
Figure 3. Current reduction in cells expressing F303V cRNA. Representative Kv1.1 (a) and Kv1.1/1.2 (c) 
current traces recorded 5 days after oocyte injection at +60 mV from a holding potential of −80 mV. Bar 
graphs showing mean reduction in (b) Kv1.1 (n = 10 cells) and (d) Kv1.1/1.2 (n = 8) current amplitudes by the 
mutation (*p < 0.005, **p < 0.001, ***p < 0.0001).
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the Kv1.1 homotetramer was changed by the mutation. The Kv1.1WT channel exhibited more residual current in 
comparison to the other two groups (p < 0.05, n = 6) (Fig. 7a). We did not observe any difference in the residual 
current between the Kv1.1WT/Kv1.2 and Kv1.1F303V/Kv1.2 channels (Fig. 7b). Recovery from inactivation which is 
an indicator of refractory period, was investigated using a double-pulse protocol whereby consecutive +60 mV 
Figure 4. Effect of F303V on the voltage-dependence of current activation. Representative Kv1.1WT (a) and 
Kv1.1F303V (b) whole-cell current families. Tail currents for Kv1.1WT (d) and Kv1.1F303V (e) were recorded at 
−50 mV preceded by several pre-pulse voltage commands. Arrows point out tail current amplitudes recorded 
after the indicated pre-pulse voltage commands. Kv1.1 (c) and Kv1.1/1.2 (f) activation (Po-V) curves derived 
from peak amplitudes of tail currents plotted as a function of pre-pulse potentials, and fitted with a Boltzmann 
function. For homomeric and heteromeric channels F303V mutation resulted in a right shift of the open 
probability curve to more positive potentials.
Channel Activation Inactivation Window Recovery
V1/2 (mV) k V1/2 (mV) k Peak (mV) Area τF (ms) τS (s)
Kv1.1WT −25 ± 0.3 6 ± 0.3 −38 ± 0.3 3 ± 0.3 −33 1 64 ± 14 2.5 ± 0.2
Kv1.1WT/F303V −13 ± 0.3* 9 ± 0.3* −34 ± 0.4* 4 ± 0.3 −27 0.8 69 ± 18 2.6 ± 0.3
KvF303V +11 ± 0.4* 8 ± 0.4* −18 ± 0.5* 5 ± 0.5† −7 0.4 30 ± 6* 2.6 ± 0.2
Kv1.1WT/1.2 −16 ± 0.4 9 ± 0.3 −31 ± 0.9 4 ± 0.9 −26 1 110 ± 2 6 ± 0.1
KvF303V/1.2 0 ± 0.5# 12 ± 0.4# −22 ± 0.6# 5 ± 0.5 −16 0.6 44 ± 5# 2 ± 0.1#
Table 1. Biophysical parameters. V1/2 and k represent voltage for half-maximal activation and slope factor 
determined from Boltzmann fits; mean ± SE. n = 6 for each channel group. *,†Significantly different from 
Kv1.1WT (*p < 0.0001, †p < 0.005). #Significantly different from Kv1.1WT/1.2 (p < 0.0001).
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pulses lasting 5 seconds are separated by interpulse intervals of increasing durations ranging from 0.010 to 21 s. 
The peak current amplitudes of the second pulses were divided by the first ones, and the values were then plotted 
as a function of the interpulse interval and fitted with a double exponential function (Fig. 7d and f). As indicated 
in the figures, the rate of recovery from inactivation was increased for the channels with the F303V mutation. 
The τfast time constant of inactivation recovery derived from the channels with the mutation were at least two 
fold smaller than that of their respective WT controls, indicating a faster recovery. There was no difference in 
τfast between Kv1.1WT/F303V and Kv1.1WT. On the other hand, for τslow, a significant difference was observed only 
between Kv1.1F303V/Kv1.2 and Kv1.1WT/Kv1.2 (Table 1).
In-silico Structural analysis. The F303V mutation reported here occurs on the important and mobile 
helix S4 (Fig. 8, red helix) of the voltage sensing domain and corresponds to the F305 residue in the Kv1.2 crys-
tal structure39 (Figure S3). In the open-state, the S4 helix is stabilized by salt bridges formed by voltage-sensing 
positively charged residues R2, R3, R4, K5 and R6 (dotted lines in Fig. 8b and c, R2 salt bridge is not shown). Our 
Figure 5. Effect of mutation on channel activation and deactivation kinetics. Activation kinetics were derived 
from the rising phase of currents evoked by depolarizing pulses (−20 to +80 mV), lasting 300 ms from a 
holding potential of −80 mV. Deactivation kinetics were derived from tail currents recorded at potentials 
−20 to −80 mV (pre-pulse potential +20 mV). Normalized and superimposed representative Kv1.1 (a) and 
Kv1.1/1.2 (d) activating currents were recorded at +20 mV, and Kv1.1 (b) and Kv1.1/1.2 (e) deactivating 
currents recorded at −50 mV. Activating and deactivating current traces were fitted with double and single 
exponential functions, respectively. Time constants of the currents were plotted as a function of membrane 
potential for Kv1.1 (c) and Kv1.1/1.2 (f) channels. Plots show that mutation results in slower activation but faster 
deactivation. The data points are mean ± SE of 8 cells.
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structural analysis shows that the F303 residue is appropriately positioned to interact with L339 and I335 of the S5 
helix of a neighboring subunit (indicated as L339B and I335B on S5 helix subunit B in Fig. 8b and c). In addition, 
both L339 and I335 residues are somewhat exposed to the hydrophobic environment of the lipid bilayer.
Discussion
In this study, we present a novel mutation in the KCNA1 gene found in a patient displaying typical signs and 
symptoms of EA1. The mutation results in the substitution of a phenylalanine with a valine in position 303. The 
phenylalanine at this position is highly conserved through evolution, thereby emphasising the mutational sub-
stitution as a causal role for the symptoms observed and highlighting its importance for normal channel gating.
Consistent with previous reports on genetic defects in KCNA1 associated with EA124, the Kv1.1F303V mutation 
resulted in a remarkable loss of function, with about 96% macroscopic current decrease when the mutation was 
expressed alone. The reduction in current amplitude was observed over several days after cRNA injection and at 
+60 mV, i.e. at maximal activation of both WT and F303V channels. This suggests mutant channels may not be as 
readily expressed in the membrane as the WT channels (possibly due to retention in the endoplasmic reticulum, 
defective membrane trafficking, or enhanced protein degradation). When F303V was co-expressed with WT 
Kv1.1 subunits at a 1:1 ratio there was a 55% decrease in current amplitude, and the currents displayed kinetics 
intermediate between those of homomeric F303V and homomeric WT channels, yet closer to the WT parame-
ters. This is probably because, in co-expression experiments, only a few mutant channels and some heteromeric 
channels are expected to reach the membrane, making the voltage-dependent parameters closer to those of the 
WT.
The F303V mutation alters the voltage-dependence and of Kv1.1, shifting the half-maxiamal activation 
voltage 36 mV towards more positive potentials compared to WT. Although the mutation is positioned in the 
voltage-sensing S4 segment of the channel, it is still quite surprising that phenylalanine, a neutral non-polar resi-
due, causes such a remarkable impact on gating. While expectedly, a mutation that replaces the positively charged 
Arg (R307) with a Cys in the S4 segment, reported for another EA1 patient, altered the voltage-depedence of 
Kv1.131. The F303V-induced depolarizing shift was evident in both the activation and inactivation phases of the 
channel, and was hence apparent in the window current. Moreover, the F303V mutation resulted in a deceleration 
of activation kinetics and acceleration of deactivation kinetics confirming a resilient effect on channel gating. 
These effects were also evident when the F303V mutation was expressed in the Kv1.1/1.2 channel, which is in 
agreement with a previous study demonstrating altered kinetics and voltage-dependence of Kv1.1/1.2 channels 
Figure 6. Effect of mutation on voltage-dependence of slow inactivation of Kv1.1 channels and on window 
currents. Cells were depolarized to various pre-pulse potentials, from −80 mV to +20 mV in +10 mV 
increments for 20 seconds, and then held at +40 mV test potential for 200 msec. Peak current amplitudes 
recorded at test potential of +40 mV were normalized (I/Imax) and these values were plotted as a function of 
the pre-pulse potentials and fitted with a Boltzmann function. The mutation resulted in the positive shift of the 
inactivation-voltage relationships for both homomeric (a) and heteromeric (b) channels. F303V reduced both 
(c) Kv1.1 and (d) Kv1.1/1.2 window currents (the triangular areas under the overlapping point of the activation 
and inactivation curves of the respective channel).
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bearing EA1 mutations, thereby confirming the finding that mutations in a single gene coding for a subunit may 
disrupt the functions of other closely associated subunits21.
Figure 7. Effect of F303V mutation on slow inactivation, residual current and recovery. (a and b) Bar graphs 
showing residual current after slow inactivation for Kv1.1 (a) and Kv1.1/1.2 (b) channels. A double-pulse 
recovery protocol at a depolarizing voltage of +60 mV was used to derive currents from (c) Kv1.1WT (top), 
Kv1.1WT/F303V (middle) and Kv1.1F303V (bottom) channels, and from (e) Kv1.1WT/1.2 (top) and Kv1.1F303V/1.2 
(bottom) channels. Normalized peak current amplitudes were plotted as a function of interpulse interval 
for Kv1.1 (d) and Kv1.1/1.2 channels (f). The solid lines show the fit with the double exponential function 
Y = Y0 + SpanFast*(1-exp(-KFast*X)) + SpanSlow*(1-exp(-KSlow*X)), where SpanFast = (Plateau-
Y0)*PercentFast*.01, SpanSlow = (Plateau-Y0)*(100-PercentFast)*.01 and K is the rate constant. Data points 
are mean ± SE of 6 cells.
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The recovery from slow inactivation was faster for channels carrying the mutation indicating a destabilization 
of the inactivated-state. A more rapid recovery means F303V channels will be available faster and contribute 
more readily towards the generation of new action potentials. Decreased current amplitudes, reduced window 
currents, increased recovery rate, and depolarizing shifts in the voltage-dependence of Kv1.1 will, altogether, 
more than likely result in an increase in neuronal excitability that in EA1 would manifest as ataxic attacks and 
myokymia, as observed in the proband and family members carrying the mutation. As shown previously21, an 
altered delayed-rectifier function as a consequence of EA1 mutation in heteromeric channels comprising Kv1.1 
and Kv1.2 subunits, known to be expressed at the presynaptic terminals of basket cells, increases membrane excit-
ability, prolongs action potential duration, and enhances Ca2+ ion influx21, 38. Larger amounts of γ-aminobutyric 
acid (GABA) released from basket cell terminals would then alter inhibitory outputs of relevant Purkinje cells 
likely resulting in ataxia.
Of particular interest is the presence of nystagmus in the extreme lateral gaze of the proband’s family member 
pt II1. Although nystagmus has not been clearly associated thus far with EA1, its appearance as a symptom here is 
not completely surprising. After all, vestibulogenic stimulations trigger attacks of ataxia in EA1 patients and the 
vestibular system is an established regulator of our sense of balance, position in space, adaptive control of posture 
and a number of eye movements including the vestibulo−ocular reflexes. There is evidence for the abundant 
expression of Kv1.1 channels in both vestibular nuclei45 and ganglion cells46 where they, along with other distinct 
K+ channels, control the excitability, discharge pattern and resonance properties of neurons of the vestibular 
system47, 48. Accordingly, the nystagmus may be the result of a mutation-induced effect on vestibular function.
Altered Ca2+ homeostasis was observed in the motor axons of Kv1.1V408A/+ mice, a rodent model of EA118. 
By investigating the neuromuscular transmission of these ataxic mice and their susceptibility to physiologically 
relevant stressors, direct evidence was provided for the generation of neuromyotonic/myokymic activity by 
motor nerve axons with dysfunctional Kv1.1/Kv1.2 channels and altered Ca2+ signals. Furthermore, this study 
also pointed out the significant role that juxtaparanodal K+ channels composed of Kv1.1/Kv1.2 subunits play in 
dampening the excitability of motor nerve axons during fatigue or ischemic insults18. Collectively, these findings 
Figure 8. Model structure of the human Kv1.1 potassium channel in the open-state. (a) The structure of the 
tetrameric channel is shown with each of the four polypeptide subunits colored overall grey, green, pink and 
blue. The position of the membrane is illustrated by a grey band and the brightly colored helices in the top left of 
the figure are shown in the expanded Figures b and c. (b) The membrane spanning region of interest depicting 
four helices of one subunit (S1 yellow, S2 orange, S3 lavender and S4 red) and one helix from a neighboring 
subunit (S5B, blue) are shown. Helix S3 lies in front of the other helices and is rendered transparent for clarity. 
Significant side chains are drawn in stick representations and binding partners indicated by black dotted lines 
between them. These include R3-E187, R3-E225, R4-E225, K5-D258, R6-D258, F303-L339B and F303-I335B. 
The predicted position of the V303 mutant side chain is also shown. (c) Illustrates the same structure as depicted 
in B rotated ninety degrees towards the observer. The stacking of F300 and F303 is well illustrated in this figure.
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are consistent with the abnormal neuromuscular transmission exhibited by our proband during resting condi-
tions (myokymia), physical exercise or when challenged with high frequency stimuli to ulnar and tibial nerves.
Channel kinetics can be assessed with a voltage protocol in which the membrane is depolarized to open the 
channels and then hyperpolarized to close them. In general, the rate of closure is voltage dependent; it becomes 
faster as the membrane voltage is made more negative. The assessment of the time constants of deactivation as a 
function of voltage for wild-type channels clearly shows (Fig. 5) that the more negative the repolarization poten-
tial the faster the closure of the channels. However, when F303 is replaced by a valine the channels take a much 
shorter time to close. The negative Vm and faster closure suggest that the Phe to Val substitution energetically 
favors a closed channel state relative to an open one. This emphasizes the importance of a Phe side chain at this 
position for proper conformational equilibria of the channel. In Shaker channels, the presence of an intrinsically 
repulsive electrostatic interaction between the face of the aromatic residue F481 and the net negative charge of the 
acidic side chain E395 (located on an adjacent subunit) that may serve to inherently destabilize the channel open 
state has been previously proposed37. Moreover, we have previously shown that the EA1 mutation E325D (corre-
sponding to E395 in Shaker channels) alters the open-state stability of both homomeric Kv1.123 and heteromeric 
Kv1.1/Kv1.221 channel types. Likely, these effects could account for an altered interaction between the E325 resi-
due with either F411 (Kv1.1) or F413 (Kv1.2) in the adjacent S6 segment (corresponding to F481 in Shaker chan-
nels) in accordance with the findings discussed above37. Thus, open-state destabilization via aromatic-dependent 
interactions appears a mechanism through which EA1 mutations alter channel function and result in disturbed 
electrical excitability and prolonged action potential repolarization in excitable cells21, 38.
The mutation reported here occurs on the mobile helix S4 that is stabilized by salt bridges formed by the 
voltage-sensing positively charged residues R2, R3, R4, K5 and R6 when the channel is in the open position (see 
Fig. 8). We show here that the structure is further stabilized by hydrophobic interactions between side chains 
including F300 and F303 which lie in a staggered arrangement in the S4 310 helix (Fig. 8c). Such arrangements of 
aromatic amino acids near the C terminal ends of alpha helices has been shown to have a stabilizing influence44. 
In particular, the structural analysis indicates that F303 interacts with L339 (F303 CG1 to L339 CD1 is 4.2 Å) 
and I335 (F303 CE1 to I335 CG2 is 4.5 Å) residues positioned in the S5 helix of a neighboring subunit and, since 
these latter residues are somewhat exposed to the hydrophobic environment of the membrane, they probably 
also contribute stabilizing interactions with the phospholipids therein. The substitution of F303 by the smaller 
valine in the F303V mutant will either reduce or abolish the effectiveness of any of these interactions (V303 CG1 
to L339 CD1 is 6.8 Å, V303 CG2 to I335 CG2 is 6.7 Å), resulting in a less stable open- and inactivated-state of 
the channel. The remarkable effect of the mutation also on the voltage-dependence and activation kinetics of the 
channel suggests that the abnormal interaction of V303 with L339 and I335 will also perturb the transient salt 
bridges formed by the gating-charge residues with acidic residues on S1 and S2 (Fig. 8) and with lipid negatively 
charged phosphodiester groups during activation, impeding the transitions underlying opening and reducing the 
voltage sensitivity of the channel.
During the closing of the channel, helix S4 is considered to undergo large conformational changes including 
rotation (up to 120°; anticlockwise as viewed in Fig. 8c) and translation (approximately 10 Å; downwards as 
viewed in Fig. 8b)49. This movement has to occur within the confines of the membrane, within the VSD core 
formed by helices S1, S2 and S3 and is powered by the hyperpolarization of the membrane. During this process 
arginine R1 becomes proximal to phenylalanine F232. Moreover, it is also assumed that the 310 helix reverts to a 
more favorable alpha helical conformation during this process which would misalign the stacked arrangement of 
F300 with F303. It is tempting to speculate that the bulky side chain of phenylalanines may restrict this motion 
and that replacement with valine at position 303 could expedite the open to the closed transitions. Whether or 
not valine at position 303 may stabilize the closed resting state of the channel remains undeterminable due to the 
lack of crystal structures of the channel in the closed conformation.
In conclusion, we found a new mutation in KCNA1 (F303V) and demonstrated that the reduced current 
amplitudes and altered gating properties of the channel account for its pathophysiological impact. Remarkably, 
our findings indicate that the presence of an aromatic residue (phenylalanine) adjacent the positively charged 
residue (Lys 304) in the S4 segment, is crucial for proper Kv1.1 channels gating likely by controlling the overall 
interactions taking place between S4 and the neighboring alpha helixes. This may be regarded as a new mecha-
nism by which an aromatic residue fine-tunes conformational equilibria in Kv1.1 channels. In a much broader 
sense, understanding these “experiments” of Nature that result in overt channelopathies is helping us to unravel 
the molecular workings of the channels involved.
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